Laronidase Completed Phase 4 Trials for Mucopolysaccharidosis Type I (MPS I) / Hurler-Scheie Syndrome / Scheie Syndrome / Mucopolysaccharidosis IH Treatment

IndicationsStatusPurposePhase
CompletedTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT00144768A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients
NCT00144781A Dose-optimization Study of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I (MPS I) Disease